

Complete mesocolic excision vs. standard right hemicolectomy trial

Submission date 17/08/2016	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 24/08/2016	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 30/12/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Jim Khan

Contact details
Queen Alexandra Hospital
Portsmouth
United Kingdom
PO6 3LY

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
v1.0

Study information

Scientific Title

COMplete Mesocolic Excision vs. standard of care right hemicolectomy randomised controlled Trial

Acronym

COMET

Study objectives

Complete mesocolic excision and central vascular ligation results in a larger specimen with more lymph nodes than standard of care right hemicolectomy surgery.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multi-centre cluster randomised controlled trial

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Right sided colonic adenocarcinoma

Interventions

Intervention - CME/CVL right hemicolectomy

Control - standard of care right hemicolectomy

Intervention Type

Procedure/Surgery

Primary outcome measure

1. Size of resection specimen
2. Number of lymph nodes present

Secondary outcome measures

1. Operative time (minutes, intraoperative)
2. Blood loss (ml, intraoperative - swab weight and suction volume)

3. Length of hospital stay (postoperative days)
4. Early morbidity (30 day postoperative complications, Clavien-Dindo Classification, prospective observational recording from case notes and clinical team)
5. Surgical technique (open, laparoscopic or robotic, size of specimen, number of lymph nodes and above secondary outcomes)
6. Three year disease free and overall survival (observational recording from MDT records)
7. Specimens not compatible with CME/CVL surgery (Histopathological and/or operative video assessment - interventional arm only)
8. Extent of standard of care right hemicolectomy surgery (specimen size and number of lymph nodes, post-operative histopathological assessment)

Overall study start date

02/01/2017

Completion date

31/05/2019

Eligibility

Key inclusion criteria

1. Age 18+ years
2. Provision of written informed consent
3. Biopsy proven colonic adenocarcinoma located proximal to the mid transverse colon
4. Acceptable clear distal margin possible without division of the middle colic vessels
5. Local MDT recommends right hemicolectomy
6. Treatment undertaken with curative intent
7. Elective/scheduled operation
8. Patient assessed as fit for surgery
9. Minimal staging investigations performed - CT chest/abdomen/pelvis and full colonic assessment

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

80

Key exclusion criteria

1. Patient refusal
2. Any neoadjuvant treatment (including stenting)
3. Treatment undertaken with palliative intent

4. Emergency surgery (unplanned resection within 48hrs of admission)
5. More extensive colonic resection surgery required or performed (extended right hemicolectomy - division of all middle colic vessels, subtotal colectomy)
6. R1/R2 on histopathological assessment

Date of first enrolment

01/10/2018

Date of final enrolment

01/05/2019

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

University College London Hospitals NHS Foundation Trust

235 Euston Road

London

United Kingdom

NW1 2BU

Study participating centre

Queen Alexandra Hospital

Cosham

Portsmouth

United Kingdom

PO6 3LY

Study participating centre

St Mark's Hospital

Northwick Park, Watford Road, Harrow

London

United Kingdom

HA1 3UJ

Study participating centre

Leeds Teaching Hospitals NHS Trust

St James's University Hospital

Leeds

United Kingdom
LS9 7TF

Study participating centre
Portsmouth Hospitals NHS Trust
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
United Kingdom
PO6 3LY

Sponsor information

Organisation
Portsmouth Hospitals NHS Trust, UK

Sponsor details
De La Court House
Queen Alexandra Hospital
Portsmouth
England
United Kingdom
PO6 3LY

Sponsor type
Hospital/treatment centre

ROR
<https://ror.org/009fk3b63>

Funder(s)

Funder type
Charity

Funder Name
Pelican Cancer Foundation

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

31/05/2020

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request

IPD sharing plan summary

Available on request